Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Tanner Rawlings

Urology Rockwall, TX Medical Doctor

NPI 1558897579 CMS profile 5706420

890 Rockwall Pkwy Ste 110, Rockwall, TX 75032

Open in the dashboard

General payments

$6,363

147 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tanner Rawlings of Rockwall, TX is reported in the CMS Open Payments database as having received $6,363 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,321 42
2024 General $1,740 47
2023 General $2,758 43
2022 General $543 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tanner Rawlings
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Tanner Rawlings were reported at $1,321. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Tanner Rawlings Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $543 $476 $143–$1,263 $149
2023 $2,758 $560 $168–$1,461 $160
2024 $1,740 $563 $170–$1,464 $164
2025 $1,321 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $2,027 23 payments
  2. PROCEPT BioRobotics Corporation $781 8 payments
  3. Coloplast Corp $500 5 payments
  4. Janssen Biotech, Inc. $426 7 payments
  5. Sumitomo Pharma America, Inc. $307 12 payments
  6. Astellas Pharma US Inc $296 10 payments
  7. Ferring Pharmaceuticals Inc. $256 10 payments
  8. Dendreon Pharmaceuticals LLC $174 7 payments
  9. Ambu Inc. $140 2 payments
  10. Merck Sharp & Dohme Corporation $127 5 payments
  11. Other $1,330 58 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,455 136 payments
  2. Travel and Lodging $1,808 10 payments
  3. Education $100 1 payment
Products named General payments · program years 2022–2025
  1. AQUABEAM SYSTEM $760 7 payments
  2. Titan $500 5 payments
  3. ADSTILADRIN $256 10 payments
  4. ERLEADA $240 5 payments
  5. LithoVue $211 4 payments
  6. XTANDI $177 9 payments
  7. PROVENGE $174 7 payments
  8. GEMTESA $159 7 payments
  9. Lumenis Pulse 120H $148 2 payments
  10. RYBREVANT $138 1 payment
  11. Other $2,645 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,014

Median for Urology: 1,053

Drug cost

$431,317

Median for Urology: $101,464

Branded share of claims

28.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 15 $190,407
Myrbetriq Mirabegron Brand 128 $89,819
Orgovyx Relugolix Brand 24 $59,106
Gemtesa Vibegron Brand 30 $35,371
Mirabegron Er Mirabegron Brand 29 $12,797
Tamsulosin Hcl Generic 599 $9,528
Estradiol Generic 114 $8,929
Methenamine Hippurate Generic 81 $6,864
Finasteride Generic 217 $3,183
Potassium Citrate Er Potassium Citrate Brand 33 $2,949

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$240,804

Of which drugs: $34,958

Medicare patients

632

Average age 75

Services billed

6,683

202 women, 430 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 39%
Ischemic heart disease 35%
Chronic kidney disease 35%
Depression 27%
Atrial fibrillation 24%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $127
$127 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $83
  • PFIZER INC. $13
$96 24 —
POSLUMA
  • Blue Earth Diagnostics Limited $49
$49 — —
MYRBETRIQ
  • Astellas Pharma US Inc $47
$47 128 —
LYNPARZA
  • Merck Sharp & Dohme Corporation $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record